CA-CEPTON-TECHNOLOGIES
18.10.2019 00:02:05 CEST | Business Wire | Press release
A new technology partnership is set to transform road tolling for both providers and motorists alike by utilizing the latest advances in lidar technology and data analytics.
Cepton Technologies, Inc. has collaborated with industrial perception and machine learning experts, MechaSpin, to develop a lidar-based solution that produces detailed 3D classification of vehicles in real time for automated tolling applications. This next-generation solution combines Cepton’s Sora-P60 with MechaSpin’s MSx software to enable immediate profiling and classification of vehicles at highway speeds in a wide range of weather and lighting conditions.
Traditional tolling systems often depend on physical infrastructure to reduce vehicle speed, or tollbooths to allow for manual processing, which can cause congestion and frustration amongst motorists. Advanced systems that allow for faster tolling, however, are often subject to abuses such as leakage, while road-based sensors often fail due to wear and tear.
Cepton and MechaSpin’s solution addresses such challenges by eliminating the need for physical infrastructure while providing accurate data, such as vehicle velocity, size and axle count, in a format that can be integrated with other sensor, data capture and billing systems. At the same time, the hardware is designed for aerial installation and contains minimal moving parts, reducing the likelihood of failure.
Neil Huntingdon, Cepton’s VP of Business Development, said: “Our partnership with MechaSpin is founded on both businesses’ deep understanding of the unique and powerful capabilities of lidar, especially when it is teamed with problem solving software solutions.
“We believe that this partnership will bring major innovations to the tolling industry. Our Sora-P60 lidar delivers an unrivalled scan speed at 380Hz, making it possible to profile vehicles as they pass at highway speeds. Our partnership with MechaSpin will allow for faster, more accurate and lower cost management of our transport infrastructure as the number of vehicles continues to grow globally.”
Danny Kent, PhD, MechaSpin’s President, added: “The tolling industry lacks an integrated end-to-end solution for deploying 3D lidar for vehicle classification and tracking. MechaSpin and Cepton have partnered to deliver a solution for this need. Cepton's lidar technology coupled with MechaSpin's MSx Processing Engine offers a robust solution for tolling, intermodal and other transportation industry applications.”
Cepton will be showcasing its state-of-the-art lidar solutions at the 26th ITS World Congress in Singapore from October 21 to October 25, 2019. Please visit Cepton’s booth (B04) for more information or to arrange a live demo.
Founded in 2016 by Dr. Jun Pei and Dr. Mark McCord, Cepton is the only company in the industry to ship high-performance and low-cost lidar sensors directly to customers.
Lidar technology is not new, however its usage across industries is growing thanks to its power efficient, environmentally agnostic qualities. Like bats, which use sound waves during echolocation to measure distances and determine the location of an object, lidar utilises light waves from a laser to send a pulse of light and measure the amount of time it takes to reflect back from objects, making it possible to measure the distance between them. Since the speed of light is constant, distance can be easily calculated by measuring the time it takes for the beam to return.
Lidar systems use these pulses to create three-dimensional point clouds of their surrounding area, providing cars and other smart machines with highly accurate perception data to autonomously navigate.
Cepton's Micro Motion Technology (MMT™) is unique to the industry. Unlike traditional beam-steering technologies, such as spinning lidar and micro-electronical mechanical systems (MEMS), Cepton’s MMT architecture enables a mirrorless, frictionless and rotation-free system to increase the durability, reliability and manufacturability of the product, while delivering industry-leading range and resolution for highly accurate 3D sensing.
For more information about Cepton Technologies Inc., visit www.cepton.com
For more information about MechaSpin visit www.mechaspin.com
About Cepton Technologies, Inc.
Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.
Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.
Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines.
For more information, visit: http://www.cepton.com/ .
Cepton is headquartered in San Jose, California, USA.
It also has offices in Germany, Canada and UK.
About MechaSpin
MechaSpin is an experienced Systems Integrator and Solution Provider dedicated to using lidar technology to make the world safer, more efficient and more productive. MechaSpin’s MSx Processing Engine provides advanced signal processing and machine learning algorithms for 3D lidar data.
Founded in 2010, MechaSpin is led by engineers that started their careers as participants in the DARPA Grand Challenges, fielding lidar technology for autonomous robotic vehicles. MechaSpin’s team is focused on bringing sensors, algorithms and technologies from the self-driving car industry into industrial markets such as material handling, tolling, port and terminal, intermodal, and more.
For more information, visit: http://www.mechaspin.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
